Puma Biotech (PBYI) Tops Q2 EPS by 9c ; Offers Guidance

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.10, $0.09 better than the analyst estimate of $0.01. Revenue for the quarter came in at $54.6 million versus the consensus estimate of $51.73 million.

GUIDANCE:

Puma Biotech sees Q3 2023 revenue of $51-53 million, versus the consensus of $51.73 million.

Puma Biotech sees FY2023 revenue of $205-210 million, versus the consensus of $231.4 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance